Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Precursor lesions of vulvar squamous cell carcinoma - histology and biomarkers: A systematic review.

Dasgupta S, Ewing-Graham PC, Swagemakers SMA, van der Spek PJ, van Doorn HC, Noordhoek Hegt V, Koljenović S, van Kemenade FJ.

Crit Rev Oncol Hematol. 2020 Jan 15;147:102866. doi: 10.1016/j.critrevonc.2020.102866. [Epub ahead of print] Review.

2.

Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions.

Leeman A, Jenkins D, Del Pino M, Ordi J, Torné A, Doorbar J, Meijer CJLM, van Kemenade FJ, Quint WGV.

Cancer Med. 2020 Feb 5. doi: 10.1002/cam4.2855. [Epub ahead of print]

3.

Relevance of routine pathology review in cervical carcinoma.

van Beekhuizen HJ, Freulings MD, Dasgupta S, van Kemenade FJ, Ewing-Graham PC, van Doorn HC.

Virchows Arch. 2020 Jan 9. doi: 10.1007/s00428-019-02743-1. [Epub ahead of print]

PMID:
31919628
4.

The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.

Kooyker AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, Spaander MCW, Buskermolen M, van Vuuren HJ, Kuipers EJ, van Kemenade FJ, Ramakers C, Thomeer MGJ, Dekker E, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Int J Cancer. 2019 Dec 19. doi: 10.1002/ijc.32839. [Epub ahead of print]

PMID:
31853977
5.

Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study.

Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, Vedder JEM, Schuurman R, van den Brule AJC, van der Linden HC, Hinrichs JWJ, Molijn A, Hoogduin KJ, van Hemel BM, de Kok IMCM.

BMC Med. 2019 Dec 11;17(1):228. doi: 10.1186/s12916-019-1460-0.

6.

Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.

van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP.

J Clin Endocrinol Metab. 2020 Mar 1;105(3). pii: dgz137. doi: 10.1210/clinem/dgz137.

PMID:
31665318
7.

Cryo-Gel embedding compound for renal biopsy biobanking.

Snijders MLH, Zajec M, Walter LAJ, de Louw RMAA, Oomen MHA, Arshad S, van den Bosch TPP, Dekker LJM, Doukas M, Luider TM, Riegman PHJ, van Kemenade FJ, Clahsen-van Groningen MC.

Sci Rep. 2019 Oct 24;9(1):15250. doi: 10.1038/s41598-019-51962-8.

8.

Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.

Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MCW, Opstal-van Winden AWJ, Ramakers C, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30896-1. doi: 10.1016/j.cgh.2019.08.021. [Epub ahead of print]

9.

The impact of knowledge of HPV positivity on cytology triage in primary high-risk HPV screening.

Aitken CA, Holtzer-Goor KM, Uyterlinde A, van den Brule AJ, van der Linden HC, Huijsmans CJ, de Kok IM, van Kemenade FJ.

J Med Screen. 2019 Dec;26(4):221-224. doi: 10.1177/0969141319864991. Epub 2019 Jul 25. No abstract available.

10.

Hospital implementation of minimally invasive autopsy: A prospective cohort study of clinical performance and costs.

Wagensveld IM, Hunink MGM, Wielopolski PA, van Kemenade FJ, Krestin GP, Blokker BM, Oosterhuis JW, Weustink AC.

PLoS One. 2019 Jul 16;14(7):e0219291. doi: 10.1371/journal.pone.0219291. eCollection 2019.

11.

Grading immunohistochemical markers p16INK4a and HPV E4 identifies productive and transforming lesions caused by low- and high-risk HPV within high-grade anal squamous intraepithelial lesions.

Leeman A, Jenkins D, Marra E, van Zummeren M, Pirog EC, van de Sandt MM, van Eeden A, Schim van der Loeff MF, Doorbar J, de Vries HJC, van Kemenade FJ, Meijer CJLM, Quint WGV.

Br J Dermatol. 2019 Jul 14. doi: 10.1111/bjd.18342. [Epub ahead of print]

PMID:
31302935
12.

Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.

van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP.

Thyroid. 2019 Aug;29(8):1073-1079. doi: 10.1089/thy.2019.0053. Epub 2019 Jul 17.

PMID:
31140385
13.

Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands.

Polman NJ, de Haan Y, Veldhuijzen NJ, Heideman DAM, de Vet HCW, Meijer CJLM, Massuger LFAG, van Kemenade FJ, Berkhof J.

Prev Med. 2019 Aug;125:5-11. doi: 10.1016/j.ypmed.2019.04.025. Epub 2019 May 2.

PMID:
31054907
14.

Management and treatment of cervical intraepithelial neoplasia in the Netherlands after referral for colposcopy.

Aitken CA, Siebers AG, Matthijsse SM, Jansen EEL, Bekkers RLM, Becker JH, Ter Harmsel B, Roovers JWR, van Kemenade FJ, de Kok IMCM.

Acta Obstet Gynecol Scand. 2019 Jun;98(6):737-746. doi: 10.1111/aogs.13547. Epub 2019 Feb 27.

15.

Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.

Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, Meijer CJLM, Quint WGV, Snijders PJF, Massuger LFAG, van Kemenade FJ, Berkhof J.

Lancet Oncol. 2019 Feb;20(2):229-238. doi: 10.1016/S1470-2045(18)30763-0. Epub 2019 Jan 15.

PMID:
30658933
16.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Mar;65(3):419-426. doi: 10.1373/clinchem.2018.294041. Epub 2019 Jan 16.

PMID:
30651228
17.

Conventional Autopsy versus Minimally Invasive Autopsy with Postmortem MRI, CT, and CT-guided Biopsy: Comparison of Diagnostic Performance.

Blokker BM, Weustink AC, Wagensveld IM, von der Thüsen JH, Pezzato A, Dammers R, Bakker J, Renken NS, den Bakker MA, van Kemenade FJ, Krestin GP, Hunink MGM, Oosterhuis JW.

Radiology. 2018 Dec;289(3):658-667. doi: 10.1148/radiol.2018180924. Epub 2018 Sep 25.

PMID:
30251930
18.

Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.

Leeman A, Ebisch RMF, Kasius A, Bosgraaf RP, Jenkins D, van de Sandt MM, de Strooper LMA, Heideman DAM, Snijders PJF, Massuger LFAG, Bekkers RLM, Meijer CJLM, van Kemenade FJ, Quint WGV, Melchers WJG.

Gynecol Oncol. 2018 Nov;151(2):311-318. doi: 10.1016/j.ygyno.2018.09.006. Epub 2018 Sep 13.

PMID:
30219239
19.

Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17.

Dasgupta S, Ewing-Graham PC, van Kemenade FJ, van Doorn HC, Noordhoek Hegt V, Koljenović S.

Virchows Arch. 2018 Dec;473(6):739-747. doi: 10.1007/s00428-018-2436-8. Epub 2018 Sep 6.

20.

Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.

Leeman A, Del Pino M, Marimon L, Torné A, Ordi J, Ter Harmsel B, Meijer CJLM, Jenkins D, Van Kemenade FJ, Quint WGV.

Int J Cancer. 2019 Jan 1;144(1):160-168. doi: 10.1002/ijc.31787. Epub 2018 Nov 18.

21.

TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial.

van de Sande AJM, Koeneman MM, Gerestein CG, Kruse AJ, van Kemenade FJ, van Beekhuizen HJ.

BMC Cancer. 2018 Jun 15;18(1):655. doi: 10.1186/s12885-018-4510-7.

22.

Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.

van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP.

Thyroid. 2018 Aug;28(8):976-981. doi: 10.1089/thy.2018.0066. Epub 2018 Jul 30.

PMID:
29848239
23.

Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.

Verlaat W, Snoek BC, Heideman DAM, Wilting SM, Snijders PJF, Novianti PW, van Splunter AP, Peeters CFW, van Trommel NE, Massuger LFAG, Bekkers RLM, Melchers WJG, van Kemenade FJ, Berkhof J, van de Wiel MA, Meijer CJLM, Steenbergen RDM.

Clin Cancer Res. 2018 Jul 15;24(14):3456-3464. doi: 10.1158/1078-0432.CCR-17-3615. Epub 2018 Apr 9.

24.

Presence or Absence of Significant HPVE4 Expression in High-grade Anal Intraepithelial Neoplasia With p16/Ki-67 Positivity Indicates Distinct Patterns of Neoplasia: A Study Combining Immunohistochemistry and Laser Capture Microdissection PCR.

Leeman A, Pirog EC, Doorbar J, van de Sandt MM, van Kemenade FJ, Jenkins D, Quint WGV.

Am J Surg Pathol. 2018 Apr;42(4):463-471. doi: 10.1097/PAS.0000000000000984.

PMID:
29438174
25.

A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.

Genç CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, van Eeden S, Verheij J, van Dieren S, van Eijck CHJ, Nieveen van Dijkum EJM.

Ann Surg. 2018 Jun;267(6):1148-1154. doi: 10.1097/SLA.0000000000002123.

PMID:
28594340
26.

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.

Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2922-2929. doi: 10.1210/jc.2016-4025.

PMID:
28575418
27.

Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.

Ebisch RM, van der Horst J, Hermsen M, Rijstenberg LL, Vedder JE, Bulten J, Bosgraaf RP, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Massuger LF, Melchers WJ, Bekkers RL, Siebers AG.

Mod Pathol. 2017 Jul;30(7):1021-1031. doi: 10.1038/modpathol.2017.16. Epub 2017 Mar 17.

28.

Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.

Rozemeijer K, Naber SK, Penning C, Overbeek LI, Looman CW, de Kok IM, Matthijsse SM, Rebolj M, van Kemenade FJ, van Ballegooijen M.

BMJ. 2017 Feb 14;356:j504. doi: 10.1136/bmj.j504.

29.

Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.

Toes-Zoutendijk E, van Leerdam ME, Dekker E, van Hees F, Penning C, Nagtegaal I, van der Meulen MP, van Vuuren AJ, Kuipers EJ, Bonfrer JMG, Biermann K, Thomeer MGJ, van Veldhuizen H, Kroep S, van Ballegooijen M, Meijer GA, de Koning HJ, Spaander MCW, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Gastroenterology. 2017 Mar;152(4):767-775.e2. doi: 10.1053/j.gastro.2016.11.022. Epub 2016 Nov 24.

PMID:
27890769
30.

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.

Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.

BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924. Erratum in: BMJ. 2016 Oct 27;355:i5782.

31.

Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.

Polman NJ, Uijterwaal MH, Witte BI, Berkhof J, van Kemenade FJ, Spruijt JW, van Baal WM, Graziosi PG, van Dijken DK, Verheijen RH, Helmerhorst TJ, Steenbergen RD, Heideman DA, Ridder R, Snijders PJ, Meijer CJ.

Int J Cancer. 2017 Jan 15;140(2):423-430. doi: 10.1002/ijc.30449. Epub 2016 Oct 11.

32.

Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.

Creemers SG, van Koetsveld PM, van den Dungen ES, Korpershoek E, van Kemenade FJ, Franssen GJ, de Herder WW, Feelders RA, Hofland LJ.

J Clin Endocrinol Metab. 2016 Dec;101(12):4574-4584. Epub 2016 Sep 7. Erratum in: J Clin Endocrinol Metab. 2018 Aug 1;103(8):3115-3118.

33.

Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.

Creemers SG, van Koetsveld PM, van Kemenade FJ, Papathomas TG, Franssen GJ, Dogan F, Eekhoff EM, van der Valk P, de Herder WW, Janssen JA, Feelders RA, Hofland LJ.

Endocr Relat Cancer. 2016 Sep;23(9):727-37. doi: 10.1530/ERC-16-0266.

PMID:
27535174
34.

Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN.

Uijterwaal MH, van Zummeren M, Kocken M, Luttmer R, Berkhof J, Witte BI, van Baal WM, Graziosi GCM, Verheijen RHM, Helmerhorst TJM, van Dijken DKE, Spruijt JWM, van Kemenade FJ, Fransen-Daalmeijer N, Bekker-Lettink M, Heideman DAM, Snijders PJF, Steenbergen RDM, Meijer CJLM.

Gynecol Oncol. 2016 Oct;143(1):135-142. doi: 10.1016/j.ygyno.2016.07.089. Epub 2016 Jul 16.

PMID:
27430395
35.

FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.

Luttmer R, De Strooper LM, Dijkstra MG, Berkhof J, Snijders PJ, Steenbergen RD, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Br J Cancer. 2016 Aug 23;115(5):579-87. doi: 10.1038/bjc.2016.200. Epub 2016 Jul 14.

36.

p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.

Luttmer R, Dijkstra MG, Snijders PJ, Berkhof J, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Mod Pathol. 2016 Aug;29(8):870-8. doi: 10.1038/modpathol.2016.80. Epub 2016 May 6.

37.

The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.

Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Bulten J, Siebers AG, Bekkers RL, Melchers WJ.

Int J Cancer. 2016 Aug 1;139(3):691-9. doi: 10.1002/ijc.30090. Epub 2016 Apr 7.

38.

Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM.

Gynecol Oncol. 2016 May;141(2):341-347. doi: 10.1016/j.ygyno.2016.02.012. Epub 2016 Mar 3.

39.

Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.

Creemers SG, Hofland LJ, Korpershoek E, Franssen GJ, van Kemenade FJ, de Herder WW, Feelders RA.

Endocr Relat Cancer. 2016 Jan;23(1):R43-69. doi: 10.1530/ERC-15-0452. Epub 2015 Oct 16. Review.

PMID:
26475053
40.

Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Rozemeijer K, Penning C, Siebers AG, Naber SK, Matthijsse SM, van Ballegooijen M, van Kemenade FJ, de Kok IM.

Cancer Causes Control. 2016 Jan;27(1):15-25. doi: 10.1007/s10552-015-0678-1. Epub 2015 Oct 12.

41.

Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).

Luttmer R, De Strooper LM, Berkhof J, Snijders PJ, Dijkstra MG, Uijterwaal MH, Steenbergen RD, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, Van Baal WM, Graziosi PG, Quint WG, Heideman DA, Meijer CJ.

Int J Cancer. 2016 Feb 15;138(4):992-1002. doi: 10.1002/ijc.29824. Epub 2015 Sep 14.

42.

When is it effective to offer self-sampling to non-attendees--response.

Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1296. doi: 10.1158/1055-9965.EPI-15-0523. No abstract available.

43.

Exploring the trend of increased cervical intraepithelial neoplasia detection rates in the Netherlands.

Rozemeijer K, van Kemenade FJ, Penning C, Matthijsse SM, Naber SK, van Rosmalen J, van Ballegooijen M, de Kok IM.

J Med Screen. 2015 Sep;22(3):144-50. doi: 10.1177/0969141315580836. Epub 2015 May 14.

PMID:
25977375
44.

Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.

Luttmer R, Berkhof J, Dijkstra MG, van Kemenade FJ, Snijders PJ, Heideman DA, Meijer CJ.

J Clin Virol. 2015 Jun;67:59-66. doi: 10.1016/j.jcv.2015.04.004. Epub 2015 Apr 7.

PMID:
25959161
45.

Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.

Uijterwaal MH, Polman NJ, Van Kemenade FJ, Van Den Haselkamp S, Witte BI, Rijkaart D, Berkhof J, Snijders PJ, Meijer CJ.

Cancer Prev Res (Phila). 2015 Jun;8(6):502-8. doi: 10.1158/1940-6207.CAPR-14-0409. Epub 2015 Mar 16.

46.

Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.

Verhoef VM, van Kemenade FJ, Rozendaal L, Heideman DA, Bosgraaf RP, Hesselink AT, Melchers WJ, Massuger LF, Bekkers RL, Steenbergen RD, Berkhof J, Snijders PJ, Meijer CJ.

Gynecol Oncol. 2015 Apr;137(1):55-9. doi: 10.1016/j.ygyno.2015.01.550. Epub 2015 Feb 8.

PMID:
25667975
47.

Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?

Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):773-82. doi: 10.1158/1055-9965.EPI-14-0998. Epub 2014 Nov 28.

48.

Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.

Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GA, Ridder R, Snijders PJ, Meijer CJ.

Int J Cancer. 2015 May 15;136(10):2361-8. doi: 10.1002/ijc.29290. Epub 2014 Nov 6.

49.

Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer.

Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, Bekkers RL, Massuger LF, Steenbergen RD, Snijders PJ, Berkhof J, Meijer CJ.

Gynecol Oncol. 2014 Oct;135(1):58-63. doi: 10.1016/j.ygyno.2014.08.003. Epub 2014 Aug 8.

PMID:
25111387
50.

Acute Candida thyroiditis complicated by abscess formation in a severely immunocompromised patient.

Massolt ET, Rijneveld AW, Vernooij MW, Kevenaar ME, van Kemenade FJ, Peeters RP.

J Clin Endocrinol Metab. 2014 Nov;99(11):3952-3. doi: 10.1210/jc.2014-2528. Epub 2014 Jul 17. No abstract available.

PMID:
25033071

Supplemental Content

Loading ...
Support Center